| CORMEDIX INC. DL-,001 |
| USA |
| Gesundheit |
| US21900C3088 / A2PF3G |
| 19KA (Frankfurt) / CRMD (NASDAQ) |
| FRA:19KA, ETR:19KA, 19KA:GR, NASDAQ:CRMD |
| - |
| http://www.cormedix.com/ |
|
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, particularly in anti-infective therapies and hospital-based treatments in the United States. Its lead product..
>Volltext.. |
| 483.05 Mio. EUR |
| 453.77 Mio. EUR |
| 346.93 Mio. EUR |
| 189.74 Mio. EUR |
| 156.98 Mio. EUR |
| 2.07 EUR |
| 125.65 Mio. EUR |
| 155.01 Mio. EUR |
| 171.32 Mio. EUR |
| 1.39 |
| 353.76% |
| 886.57% |
| - |
| - |
| - |
| - |
| CORMEDIX |
| 14.08.26 |
|
||||
|
||||
|
||||
|